UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 305

Sortiert nach

The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma

Scientific reports, 2022-01, Vol.12 (1), p.36-36, Article 36

2022

Volltextzugriff (PDF)

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma

Scientific reports, 2021-06, Vol.11 (1), p.11896-11896, Article 11896

2021

Volltextzugriff (PDF)

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells

Blood, 2010-07, Vol.116 (2), p.210-217

2010

Volltextzugriff (PDF)

Tumor-specific IL-9–producing CD8⁺ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

Proceedings of the National Academy of Sciences - PNAS, 2014-02, Vol.111 (6), p.2265-2270

2014

Volltextzugriff (PDF)

Symptom clusters and quality of life in ambulatory patients with multiple myeloma

Supportive care in cancer, 2022-06, Vol.30 (6), p.4961-4970

2022

Volltextzugriff (PDF)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Frontiers in oncology, 2024, Vol.14, p.1286029-1286029

2024

Volltextzugriff (PDF)

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions

Cell death & disease, 2021-05, Vol.12 (5), p.495-495, Article 495

2021

Volltextzugriff (PDF)

Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review

Frontiers in immunology, 2024-07, Vol.15, p.1403376

2024

Volltextzugriff (PDF)

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis

Blood, 2009-10, Vol.114 (17), p.3625-3628

2009

Volltextzugriff (PDF)

Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response

JNCI : Journal of the National Cancer Institute, 2016-11, Vol.108 (11), p.djw131

2016

Volltextzugriff (PDF)

A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance

Blood, 2014-09, Vol.124 (13), p.2061-2071

2014

Volltextzugriff (PDF)

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis

Hematology (Luxembourg), 2023-12, Vol.28 (1), p.2187972

2023

Volltextzugriff (PDF)

Compassion satisfaction and compassion fatigue in haematology cancer nurses: A cross‐sectional survey

Nursing open, 2022-07, Vol.9 (4), p.2159-2170

2022

Volltextzugriff (PDF)

ALCAM regulates multiple myeloma chemoresistant side population

Cell death & disease, 2022-02, Vol.13 (2), p.136-136, Article 136

2022

Volltextzugriff (PDF)

Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma

Oncotarget, 2015-09, Vol.6 (27), p.24218-24229

2015

Volltextzugriff (PDF)

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Blood, 2012-01, Vol.119 (1), p.161-169

2012

Volltextzugriff (PDF)

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China

Frontiers in pharmacology, 2023-01, Vol.14, p.979111-979111

2023

Volltextzugriff (PDF)

Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34 + cells

Stem cell research & therapy, 2018-06, Vol.9 (1), p.158-158, Article 158

2018

Volltextzugriff (PDF)

Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials

Frontiers in oncology, 2023-06, Vol.13, p.1127112-1127112

2023

Volltextzugriff (PDF)

Pathogenesis and treatment of multiple myeloma

MedComm (2020), 2022-06, Vol.3 (2), p.e146-n/a

2022

Volltextzugriff (PDF)

Low-dose ruxolitinib shows effective in treating myelofibrosis

Annals of hematology, 2021, Vol.100 (1), p.135-141

2021

Volltextzugriff (PDF)

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma

Cancer medicine (Malden, MA), 2023-02, Vol.12 (3), p.3054-3067

2023

Volltextzugriff (PDF)

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

Haematologica (Roma), 2013-09, Vol.98 (9), p.1458-1466

2013

Volltextzugriff (PDF)

Minimal residual disease in multiple myeloma: current status

Biomarker research, 2021-10, Vol.9 (1), p.1-75, Article 75

2021

Volltextzugriff (PDF)

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

Journal of molecular medicine (Berlin, Germany), 2012-06, Vol.90 (6), p.695-706

2012

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(279)
Mit Volltextzugriff
(295)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(217)
Life Sciences & Biomedicine
(155)
Humans
(75)
Technology
(47)
Oncology
(40)
Animals
(38)
Physical Sciences
(35)
Multiple Myeloma
(31)
Female
(29)
Mice
(27)
Chemistry
(26)
Male
(26)
Hematology
(22)
Science & Technology - Other Topics
(22)
Tumors
(20)
Biotechnology & Applied Microbiology
(19)
Engineering
(19)
Environmental Sciences & Ecology
(19)
Environmental Sciences
(18)
Medicine, Research & Experimental
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells

Tumor-specific IL-9–producing CD8⁺ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

Symptom clusters and quality of life in ambulatory patients with multiple myeloma

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions

Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug–induced apoptosis

Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response

A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis

Compassion satisfaction and compassion fatigue in haematology cancer nurses: A cross‐sectional survey

ALCAM regulates multiple myeloma chemoresistant side population

Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China

Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34 + cells

Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials

Pathogenesis and treatment of multiple myeloma

Low-dose ruxolitinib shows effective in treating myelofibrosis

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

Minimal residual disease in multiple myeloma: current status

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

Suchergebnisse filtern